Search

Your search keyword '"Busaidy, Naifa L."' showing total 355 results
Start Over Author "Busaidy, Naifa L."
355 results on '"Busaidy, Naifa L."'

1. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.

Author

Hamidi, Sarah, Dadu, Ramona, Zafereo, Mark E., Ferrarotto, Renata, Wang, Jennifer R., Maniakas, Anastasios, Gunn, G. Brandon, Lee, Anna, Spiotto, Michael T., Iyer, Priyanka C., Sousa, Luana G., Akhave, Neal S., Ahmed, Salmaan, Learned, Kim O., Lu, Charles, Lai, Stephen Y., Williams, Michelle, Hosseini, S. Mohsen, Busaidy, Naifa L., and Cabanillas, Maria E.

Published
2024
Full Text
View/download PDF

2. Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades.

Author

Hensley, Sarah G, Hu, Mimi I, Bassett, Roland L, Ying, Anita K, Zafereo, Mark E, Perrier, Nancy D, Busaidy, Naifa L, Hyde, Samuel M, Grubbs, Elizabeth G, and Waguespack, Steven G

Subjects
MEDULLARY thyroid carcinoma, SYMPTOMS, OLDER patients, OVERALL survival, FAMILY history (Medicine), CHILD patients
Abstract

Context Sporadic medullary thyroid carcinoma (sMTC) rarely occurs in childhood and no studies have specifically focused on this entity. Objective To describe the clinical presentations and long-term outcomes of a large cohort of children and young adults with sMTC compared with hereditary MTC (hMTC). Methods Retrospective study of 144 patients diagnosed with MTC between 1961 and 2019 at an age ≤ 21 years and evaluated at a tertiary referral center. Results In contrast to hMTC (n = 124/144, 86%), patients with sMTC (n = 20/144, 14%) are older (P <.0001), have larger tumors (P <.0001), a higher initial stage grouping (P =.001) and have more structural disease (P =.0045) and distant metastases (DM) (P =.00084) at last follow-up, but are not more likely to die from MTC (P =.42). Among 77 patients diagnosed clinically, not by family history (20/20 sMTC and 57/124 hMTC), there was no difference in the initial stage (P =.27), presence of DM at diagnosis (P = 1.0), disease status at last follow-up (P =.13), overall survival (P =.57), or disease-specific survival (P =.87). Of the 12 sMTC tumors that underwent somatic testing, 11 (91%) had an identifiable alteration: 10 RET gene alterations and 1 ALK fusion. Conclusion sMTC is primarily a RET-driven disease that represents 14% of childhood-onset MTC in this cohort. Pediatric sMTC patients are older, present with clinical disease at a more advanced TNM classification, and have more persistent disease at last follow-up compared with hMTC, but these differences disappear when comparing those presenting clinically. Somatic molecular testing should be considered in sMTC patients who would benefit from systemic therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Recurrent Laryngeal Nerve Recovery After Neoadjuvant Therapy for BRAF-Mutated Anaplastic Thyroid Cancer

Author

Hawes, Ella E., primary, Cabanillas, Maria E., additional, Hutcheson, Kate, additional, Barbon, Carly, additional, Dadu, Ramona, additional, Busaidy, Naifa L., additional, Iyer, Priyanka Chandrasekhar, additional, Siddiqui, Sameer H., additional, Maniakas, Anastasios, additional, Wang, Jennifer Rui, additional, and Zafereo, Mark E., additional

Published
2024
Full Text
View/download PDF

5. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

Author

Hegde, Aparna, Andreev-Drakhlin, Alexander Y., Roszik, Jason, Huang, Le, Liu, Shuang, Hess, Kenneth, Cabanillas, Maria, Hu, Mimi I., Busaidy, Naifa L., Sherman, Steven I., Dadu, Ramona, Grubbs, Elizabeth G., Ali, Siraj M., Lee, Jessica, Elamin, Yasir Y., Simon, George R., Blumenschein, George R., Jr, Papadimitrakopoulou, Vassiliki A., Hong, David, Meric-Bernstam, Funda, Heymach, John, and Subbiah, Vivek

Published
2020
Full Text
View/download PDF

11. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.

Author

Hamidi, Sarah, Iyer, Priyanka C., Dadu, Ramona, Gule-Monroe, Maria K., Maniakas, Anastasios, Zafereo, Mark E., Wang, Jennifer R., Busaidy, Naifa L., and Cabanillas, Maria E.

Subjects
ANAPLASTIC thyroid cancer, IMMUNOTHERAPY, THERAPEUTICS, PROGRESSION-free survival, OVERALL survival, SURGICAL excision
Abstract

Background: The dabrafenib plus trametinib combination (DT) has revolutionized the treatment of BRAFV600E-mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival (mOS) of 5.9 months. Combination of immunotherapy with BRAF/MEK inhibitors (BRAF/MEKi) seems to improve outcomes compared with BRAF/MEKi alone, although no direct comparison is available. BRAF-targeted therapy before surgery (neoadjuvant approach) has also shown improvement in survival. We studied the efficacy and safety of DT plus pembrolizumab (DTP) compared with current standard-of-care DT alone as an initial treatment, as well as in the neoadjuvant setting. Methods: Retrospective single-center study of patients with BRAFm-ATC treated with first-line BRAF-directed therapy between January 2014 and March 2023. Three groups were evaluated: DT, DTP (pembrolizumab added upfront or at progression), and neoadjuvant (DT before surgery, and pembrolizumab added before or after surgery). The primary endpoint was mOS between DT and DTP. Secondary endpoints included median progression-free survival (mPFS) and response rate with DT versus DTP as initial treatments, and the exploratory endpoint was mOS in the neoadjuvant group. Results: Seventy-one patients were included in the primary analysis: n = 23 in DT and n = 48 in DTP. Baseline demographics were similar between groups, including the presence of metastatic disease at start of treatment (p = 0.427) and prior treatments with surgery (p = 0.864) and radiation (p = 0.678). mOS was significantly longer with DTP (17.0 months [confidence interval CI, 11.9–22.1]) compared with DT alone (9.0 months [CI, 4.5–13.5]), p = 0.037. mPFS was also significantly improved with DTP as the initial treatment (11.0 months [CI, 7.0–15.0]) compared with DT alone (4.0 months [CI, 0.7–7.3]), p = 0.049. Twenty-three patients were in the exploratory neoadjuvant group, where mOS was the longest (63.0 months [CI, 15.5–110.5]). No grade 5 adverse events (AEs) occurred in all three cohorts, and 32.4% had immune-related AEs, most frequently hepatitis and colitis. Conclusions: Our results show that in BRAFm-ATC, addition of pembrolizumab to dabrafenib/trametinib may significantly prolong survival. Surgical resection of the primary tumor after initial BRAF-targeted therapy in selected patients may provide further survival benefit. However, conclusions are limited by the retrospective nature of the study. Additional prospective data are needed to confirm this observation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer

Author

Maniakas, Anastasios, primary, Sullivan, Andrew, additional, Hu, Mimi I., additional, Busaidy, Naifa L., additional, Cabanillas, Maria E., additional, Dadu, Ramona, additional, Waguespack, Steven G., additional, Fisher, Sarah B., additional, Graham, Paul H., additional, Gross, Neil D., additional, Grubbs, Elizabeth G., additional, Perrier, Nancy D., additional, Wang, Jennifer R., additional, Gunn, Brandon, additional, Garden, Adam S., additional, Megahed, Romy, additional, Navuluri, Sriram, additional, Li, Xu, additional, Williams, Michelle D., additional, and Zafereo, Mark, additional

Published
2023
Full Text
View/download PDF

19. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer.

Author

Maniakas, Anastasios, Sullivan, Andrew, Hu, Mimi I., Busaidy, Naifa L., Cabanillas, Maria E., Dadu, Ramona, Waguespack, Steven G., Fisher, Sarah B., Graham, Paul H., Gross, Neil D., Grubbs, Elizabeth G., Perrier, Nancy D., Wang, Jennifer R., Gunn, Brandon, Garden, Adam S., Megahed, Romy, Navuluri, Sriram, Li, Xu, Williams, Michelle D., and Zafereo, Mark

Subjects
MEDULLARY thyroid carcinoma, RADIOTHERAPY, OVERALL survival
Abstract

Background: Use of postoperative radiation therapy (PORT) in locoregionally advanced medullary thyroid cancer (MTC) remains controversial. The objective was to evaluate the effect of PORT on locoregional control (LRC) and overall survival (OS). Methods: Retrospective cohort study of 346 MTC patients separated into PORT and no‐PORT cohorts. Relative indications for PORT, as well as changes in patterns of treatment, were recorded. Results: 49/346 (14%) received PORT. PORT was associated with worse OS; adjusted HR = 2.0 (95%CI 1.3–3.3). PORT was not associated with improved LRC, even when adjusting for advanced stage (Stage III p = 0.892; Stage IV p = 0.101). PORT and targeted therapy were not associated with improved OS compared to targeted therapy alone; adjusted HR = 1.2 (95%CI 0.3–4.1). Conclusions: Use of PORT in MTC has decreased and its indications have become more selective, coinciding with the advent of effective targeted therapies. Overall, PORT was not associated with improved LRC or OS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Endocrinologic Issues

Author

Hu, Mimi I., Jimenez, Camilo, Busaidy, Naifa L., Habra, Mouhammed Amir, Buzdar, Aman U., Series editor, Freedman, Ralph S., Series editor, Foxhall, Lewis E., editor, and Rodriguez, Maria Alma, editor

Published
2015
Full Text
View/download PDF

21. Targeted Therapies in Thyroid Cancer

Author

Abadin, Shabirhusain S., Busaidy, Naifa L., Perrier, Nancy D., Kazi, Rehan, Series editor, Dwivedi, Raghav C., Series editor, Pathak, K. Alok, editor, Nason, Richard W., editor, and Pasieka, Janice L., editor

Published
2015
Full Text
View/download PDF

23. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma

Author

Romero Arenas, Minerva A., Rich, Thereasa A., Hyde, Samuel M., Busaidy, Naifa L., Cote, Gilbert J., Hu, Mimi I., Gagel, Robert F., Gidley, Paul W., Jimenez, Camilo, Kupferman, Michael E., Peterson, Susan K., Sherman, Steven I., Ying, Anita, Bassett, Jr., Roland L., Waguespack, Steven G., Perrier, Nancy D., and Grubbs, Elizabeth G.

Published
2018
Full Text
View/download PDF

24. Supplementary Table 1 from Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK

Author

Vin, Harina, primary, Ching, Grace, primary, Ojeda, Sandra S., primary, Adelmann, Charles H., primary, Chitsazzadeh, Vida, primary, Dwyer, David W., primary, Ma, Haiching, primary, Ehrenreiter, Karin, primary, Baccarini, Manuela, primary, Ruggieri, Rosamaria, primary, Curry, Jonathan L., primary, Ciurea, Ana M., primary, Duvic, Madeleine, primary, Busaidy, Naifa L., primary, Tannir, Nizar M., primary, and Tsai, Kenneth Y., primary

Published
2023
Full Text
View/download PDF

25. Data from Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK

Author

Vin, Harina, primary, Ching, Grace, primary, Ojeda, Sandra S., primary, Adelmann, Charles H., primary, Chitsazzadeh, Vida, primary, Dwyer, David W., primary, Ma, Haiching, primary, Ehrenreiter, Karin, primary, Baccarini, Manuela, primary, Ruggieri, Rosamaria, primary, Curry, Jonathan L., primary, Ciurea, Ana M., primary, Duvic, Madeleine, primary, Busaidy, Naifa L., primary, Tannir, Nizar M., primary, and Tsai, Kenneth Y., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 1 from Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK

Author

Vin, Harina, primary, Ching, Grace, primary, Ojeda, Sandra S., primary, Adelmann, Charles H., primary, Chitsazzadeh, Vida, primary, Dwyer, David W., primary, Ma, Haiching, primary, Ehrenreiter, Karin, primary, Baccarini, Manuela, primary, Ruggieri, Rosamaria, primary, Curry, Jonathan L., primary, Ciurea, Ana M., primary, Duvic, Madeleine, primary, Busaidy, Naifa L., primary, Tannir, Nizar M., primary, and Tsai, Kenneth Y., primary

Published
2023
Full Text
View/download PDF

28. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series

Author

Contrera, Kevin J., primary, Gule-Monroe, Maria K., additional, Hu, Mimi I., additional, Cabanillas, Maria E., additional, Busaidy, Naifa L., additional, Dadu, Ramona, additional, Waguespack, Steven G., additional, Wang, Jennifer R., additional, Maniakas, Anastasios, additional, Lai, Stephen Y., additional, Diersing, Julia, additional, Kwon, Michael, additional, Grubbs, Elizabeth G., additional, Subbiah, Vivek, additional, Williams, Michelle D., additional, and Zafereo, Mark E., additional

Published
2023
Full Text
View/download PDF

29. PSAT385 Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer

Author

Vodopivec, Danica M, primary, Cabanillas, Maria E, additional, Busaidy, Naifa L, additional, Gule-Monroe, Maria K, additional, Zafereo, Mark E, additional, Wang, Jennifer R, additional, Williams, Michelle D, additional, Waguespack, Steven G, additional, Bassett, Roland, additional, Maniakas, Anastasios, additional, Lai, Stephen Y, additional, and Dadu, Ramona, additional

Published
2022
Full Text
View/download PDF

38. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial

Author

Busaidy, Naifa L., primary, Konda, Bhavana, additional, Wei, Lai, additional, Wirth, Lori J., additional, Devine, Catherine, additional, Daniels, Gregory A., additional, DeSouza, Jonas A., additional, Poi, Ming, additional, Seligson, Nathan D., additional, Cabanillas, Maria E., additional, Sipos, Jennifer A., additional, Ringel, Matthew D., additional, Eisfeld, Ann-Kathrin, additional, Timmers, Cynthia, additional, and Shah, Manisha H., additional

Published
2022
Full Text
View/download PDF

41. Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial

Author

Yennurajalingam, Sriram, primary, Valero, Vicente, additional, Lu, Zhanni, additional, Liu, Diane D., additional, Busaidy, Naifa L., additional, Reuben, James M., additional, Diaz Fleming, Carolina, additional, Williams, Janet L., additional, Hess, Kenneth R., additional, Basen-Engquist, Karen, additional, and Bruera, Eduardo, additional

Published
2022
Full Text
View/download PDF

42. Therapeutic Potential of Ralimetinib, a p38/MAPK14 Inhibitor, in Anaplastic Thyroid Cancer

Author

Kunnimalaiyaan, Muthusamy, primary, Dadbin, Ali, additional, Henderson, Ying, additional, Fujiwara, Elena McBeath, additional, Stephan, Clifford, additional, Nurieca, Roza, additional, Busaidy, Naifa L., additional, Wang, Jennifer R., additional, Lai, Stephan, additional, Cabanillas, Maria, additional, Zafereo, Marc E., additional, Dadu, Ramona, additional, and Hofmann, Marie-Claude, additional

Published
2022
Full Text
View/download PDF

44. RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient

Author

Bagheri-Yarmand, Rozita, primary, Busaidy, Naifa L., additional, McBeath, Elena, additional, Danysh, Brian P., additional, Evans, Kurt W., additional, Moss, Tyler J., additional, Akcakanat, Argun, additional, Ng, Patrick K. S., additional, Knippler, Christina M., additional, Golden, Jalyn A., additional, Williams, Michelle D., additional, Multani, Asha S., additional, Cabanillas, Maria E., additional, Shaw, Kenna R., additional, Meric-Bernstam, Funda, additional, Shah, Manisha H., additional, Ringel, Matthew D., additional, and Hofmann, Marie Claude, additional

Published
2021
Full Text
View/download PDF

45. RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma

Author

Grubbs, Elizabeth G., Ng, Patrick Kwok-Shing, Bui, Jacquelin, Busaidy, Naifa L., Chen, Ken, Lee, Jeffrey E., Lu, Xinyan, Lu, Hengyu, Meric-Bernstam, Funda, Mills, Gordon B., Palmer, Gary, Perrier, Nancy D., Scott, Kenneth L., Shaw, Kenna R., Waguespack, Steven G., Williams, Michelle D., Yelensky, Roman, and Cote, Gilbert J.

Published
2015

47. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers.

Author

Hofmann, Marie-Claude, Kunnimalaiyaan, Muthusamy, Wang, Jennifer R., Busaidy, Naifa L., Sherman, Steven I., Lai, Stephen Y., Zafereo, Mark, and Cabanillas, Maria E.

Subjects
THYROID cancer, KINASE inhibitors, PROTEIN kinases, ANAPLASTIC thyroid cancer, IODINE isotopes, DRUG resistance, THYROTROPIN receptors
Abstract

Protein kinases play critical roles in cell survival, proliferation, and motility. Their dysregulation is therefore a common feature in the pathogenesis of a number of solid tumors, including thyroid cancers. Inhibiting activated protein kinases has revolutionized thyroid cancer therapy, offering a promising strategy in treating tumors refractory to radioactive iodine treatment or cytotoxic chemotherapies. However, despite satisfactory early responses, these drugs are not curative and most patients inevitably progress due to drug resistance. This review summarizes up-to-date knowledge on various mechanisms that thyroid cancer cells develop to bypass protein kinase inhibition and outlines strategies that are being explored to overcome drug resistance. Understanding how cancer cells respond to drugs and identifying novel molecular targets for therapy still represents a major challenge for the treatment of these patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Endocrinologic Issues

Author

Hu, Mimi I., primary, Jimenez, Camilo, additional, Busaidy, Naifa L., additional, and Habra, Mouhammed Amir, additional

Published
2014
Full Text
View/download PDF

49. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns

Author

Nguyen, Ha, primary, Shah, Komal, additional, Waguespack, Steven G, additional, Hu, Mimi I, additional, Habra, Mouhammed Amir, additional, Cabanillas, Maria E, additional, Busaidy, Naifa L, additional, Bassett, Roland, additional, Zhou, Shouhao, additional, Iyer, Priyanka C, additional, Simmons, Garrett, additional, Kaya, Diana, additional, Pitteloud, Marie, additional, Subudhi, Sumit K, additional, Diab, Adi, additional, and Dadu, Ramona, additional

Published
2021
Full Text
View/download PDF

50. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity

Author

Maniakas, Anastasios, primary, Henderson, Ying C, additional, Hei, Hu, additional, Peng, Shaohua, additional, Chen, Yunyun, additional, Jiang, Yujie, additional, Ji, Shuangxi, additional, Cardenas, Maria, additional, Chiu, Yulun, additional, Bell, Diana, additional, Williams, Michelle D, additional, Hofmann, Marie-Claude, additional, Scherer, Steve E, additional, Wheeler, David A, additional, Busaidy, Naifa L, additional, Dadu, Ramona, additional, Wang, Jennifer R, additional, Cabanillas, Maria E, additional, Zafereo, Mark, additional, Johnson, Faye M, additional, and Lai, Stephen Y, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results